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Coagulopathy Caused by Concurrent Ciprofloxacin and Warfarin Use: 
What Other Factors Induce Coagulopathy ?
Sungmo Jung, MD, Misung Park, MD, Won Jin Kim, MD, Chang Oh Kim, MD
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Background: To assess factors affecting the prolongation of the international normalized ratio (INR) with concurrent warfarin 
and ciprofloxacin use.
Methods: A retrospective case-control study was performed at a single, 2,000-bed tertiary hospital between January 
2007 and December 2009. Thirty-three patients who were on warfarin and ciprofloxacin concurrently were enrolled. 
Demographics and clinical data were collected from medical records.
Results: Nine patients were assigned to the case group (prolonged INR) and 19 patients to the control group (normal 
INR). Activities of daily living (ADL) and total number of classes of medications taken demonstrated significant differ-
ences between the groups (15.33 vs. 7.11, p<0.001; 7.11 vs. 5.47, p=0.041). No bleeding complications occurred during 
this study.
Conclusion: As ADL reflects patient performance status and general condition of an individual, we conclude that a 
poor general condition is associated with coagulopathy in persons concurrently using warfarin and ciprofloxacin.
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INTRODUCTION
Warfarin has been the most frequently used oral anticoa- 
gulant agent for the past 50 years and is used for deep vein 
thrombosis, pulmonary thromboembolism, atrial fibrillation, 
valvular heart disease, and postprosthetic heart valve replace-
ment1-3). It is an effective oral agent that can be taken easily. 
However, because of its narrow therapeutic index, the interna-
tional normalized ratio (INR) has to be continually monito- 
red1). Despite regular INR monitoring, warfarin has a risk 
of hemorrhage and can result in major bleeding including int- 
racranial hemorrhage and gastrointestinal (GI) bleeding1,2,4).
Warfarin is a hydroxycoumarin and a vitamin K antagonist 
which inhibits synthesis of vitamin K-dependent clotting fac-
tors (factor II, VII, IX, and X) in the liver2,4,5). Therefore, vita- 
min K-containing foods or drugs can affect the INR and warfarin’s 
anticoagulation effect6). Many drugs and foods that affect the 
liver function also can change warfarin’s anticoagulation effect 
because warfarin metabolism occurs primarily in the liver, 
involving the cytochrome P450 isoenzyme2,5). Other drugs can 
interact with warfarin when taken concurrently1,4). Patient 
conditions including fever, declined liver function, and hyper-
thyroidism can increase the anticoagulation effect of warfarin, 
and there are several reports that antibiotics can increase the 
anticoagulation response6-8).
Fluoroquinolones are broad spectrum antibiotics used fre-
quently in infectious diseases. Their oral and intravenous agents 
have many advantages including excellent bioavailability, low 
toxicity, and high volume of distribution that allow the antibio- 
tics to reach effective concentrations in most tissues6,8,9). Cip- 
rofloxacin has been used frequently for urinary tract infe- 
ctions (UTI)9). Levofloxacin and moxifloxacin, which achieve 
high intracellular concentrations, have been used for commun-
ity aquired pneumonia as these antibiotics can effectively treat 
intracellular pathogens including Legionella pneumophilia and 
Myocobacterium tuberculosis. The frequency of their use has 
also increased in hospitalized patients8,10). However, because 
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Fig. 1. Flow chart of subject identification for the study. Finally, 33 patients were on warfarin
and ciprofloxacin concurrently.
many elderly hospitalized patients have medical comorbidities 
and some patients take warfarin, the concurrent use of these 
antibiotics can result in drug interactions8,10).
There are many reports of INR prolongation in patients 
on warfarin with concurrent use of antibiotics7-13). There are 
several hypotheses to explain INR prolongation. First, gut 
flora disruption resulting from antibiotic use can inhibit vitamin 
K2 synthesis13,14). Second, antibiotics that inhibit cytochrome 
P450 isozyme 2C9 can debase metabolism of the S-enantiomer 
of warfarin13,15,16).
However, most studies have not shown statistical evidence 
of INR prolongation resulting from concurrent warfarin and 
fluoroquinolone use7-13,17-20). Therefore, we considered other 
factors affecting previously reported INR prolongation in addi-
tion to concurrent use of warfarin and fluoroquinolone. The 
purpose of this study was to determine what factors can affect 
INR prolongation in the setting of concurrent drug use.
MATERIALS AND METHODS
1. Study patients, case and control groups
This single-center multivariable retrospective case-control 
study was conducted with hospitalized patients recruited from 
a 2,000-bed tertiary hospital located in Seoul, South Korea, 
between January 2007 and December 2009. We identified 
1,308 patients who were prescribed ciprofloxacin and 495 
patients who were prescribed warfarin during the study. 
Although 88 patients took both ciprofloxacin and warfarin, 
only 33 patients took the medications concurrently (Fig. 1). 
In these 33 chronically anticoagulated patients who then took 
ciprofloxacin, 9 suffered INR prolongation over 5.0 at any 
point without an increase to their warfarin dose. We enrolled 
these 9 patients for the case group. However, 19 patients 
did not show INR prolongation over 3.5 though taking cipro-
floxacin and warfarin concurrently. These patients were as-
signed to the control group (Fig. 1). All data were obtained 
from medical records, and this study was approved by the 
institutional review board of our hospital.
2. Protocol
We undertook a multivariable study to determine which 
factors affect INR prolongation in patients who had con-
currently taken ciprofloxacin and warfarin. The variables in-
cluded age, sex, activities of daily living (ADL), comorbidities, 
concurrent use of medication except for warfarin and cipro-
floxacin, and duration of hospitalization.
Comorbidities included diabetes mellitus, cancer, hyper-
tension, chronic kidney disease, and other medical diseases. 
Previous bleeding histories included GI bleeding, intracranial 
bleeding, and anemia due to bleeding of any other parts of 
body as bleeding was a complication of warfarin use. Chronic 
liver disease was also regarded because liver disease can inhibit 
warfarin metabolism.
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The Katz ADL index was used to assess function including 
bathing, dressing, toileting, feeding, continence, and transfer- 
ring. We scored one point for independent patients, two points 
for partially dependent patients, and three points for fully 
dependent patients. We added the scores for each item, and 
ADL values ranged from 6 to 18.
Medication histories, except ciprofloxacin and warfarin, 
included every drug suspected to affect the metabolism of 
warfarin. These included aspirin, antiplatelet agents, anti-in-
flammatory agents, steroids, other antibiotics, acetaminophen, 
selective serotonin reuptake inhibitor, and cytochrome P450 
inducer or inhibitor. We also included the number of types 
of medication taken concurrently with warfarin as a variable.
In addition, the infectious disease for which the patients 
required ciprofloxacin, pressure sores, admission history, and 
residence in a health care facility were included as stastistical 
variables. Patients were excluded from the study if their anti-
biotic course was completed (due to recovery), if they expired 
due to disease progression, or if they had to stop the antibiotics 
because of severe adverse drug reactions including GI bleeding 
and other severe hemorrhaging. No subjects were excluded 
due of bleeding associated complications.
A ‘pre-INR’ was measured at admission or 3 days before 
the concurrent use of ciprofloxacin and warfarin. After beginning 
the concurrent administration of ciprofloxacin and warfarin, 
the INR was measured every 3 or less days. ‘Max-INR’ was 
the maximum value of INR during this treatment status, and 
a ‘post-INR’ was done 3 days after stopping ciprofloxacin.
3. Statistical analysis
Because it was difficult to confirm a normal distribution 
for the continuous variables due to the small sample size, we 
first conducted a normality test. We conducted an independent 
two-sample t-test for the variables satisfying the normality 
test and the Mann-Whitney U test for the others. We conducted 
a chi-square test for the categorized variables. All statistical 
analyses were performed with the SAS 9.1.3 (Institute Inc., 
Cary, NC, USA).
RESULTS
Nine cases and 19 control subjects were included in this 
study. The mean age was 65.7 years, with seven patients 
(25.00%) younger than 60 years and six patients (21.43%) 
older than 80 years. Seventeen of the 28 patients (60.71%) 
were female. Twelve patients (42.86%) had two or three comor- 
bidities and two patients (7.14%) had more than six comor- 
bidities. Previous bleeding history including GI bleeding was 
reported by seven patients (25.00%). Eleven patients (39.29 
%) used ciprofloxacin for UTI and nine patients (32.14%) 
used ciprofloxacin for pneumonia. Eight patients (28.57%) 
were prescribed ciprofloxacin for other infections. The patients 
in this study took an average of 10 drugs (10.04±3.64, data 
are not shown), and these drugs were categorized into an 
average of six classes (6.00±2.00). Other characteristics of 
cases and control subjects are summarized in Table 1.
According to the normality testing, maximum INR, length 
of hospitalization, and ADL were not normally distributed in 
the cases. ADL, warfarin dosage, and length of hospitalization 
did not satisfy the normality testing in the control subjects 
(data are not shown). Statistical analysis shows that the total 
number of drug category (p=0.041), maximun INR (p<0.001), 
and ADL (p<0.001) were significantly different between the 
two groups. A statistical difference in maximum INR reflects 
that cases and control subjects are properly divided. In the 
categorized variables, no variables were statistically different 
between the groups (Table 1). Assessed drugs including acet-
aminophen, corticosteroids, GI protective drugs, selective se-
rotonin reuptake inhibitor, and cytochrome P450 inducer 
or inhibitor did not induce INR prolongation (data are not 
shown). Body mass index, pressure sores, and duration of 
treatment or hospitalization were not associated with INR 
prolongation (data are not shown).
The case group included nine patients. The most common 
reason for taking ciprofloxacin was UTI (5 patients). Other 
indications included pneumonia, acute gastroenteritis, celluli-
tis, and empirical use due to fever. The case patients had 
three to five comorbidities. The duration of hospitalization 
varied from six days to 375 days. The mean pre-INR was 
2.33 and the maximum INR varied from 5.21 to 14.68 (mean 
maximum INR, 7.11). The INRs decreased to the desired 
value (mean INR, 2.06) after ciprofloxacin cessation (Fig. 2) 
(Tables 2, 3).
There were no significant complications resulting from INR 
prolongation. After treatment with ciprofloxacin, most pa-
tients reported a spontaneous return to the desired INR range, 
though some patients were required to hold their warfarin 
temporarily. One patient experienced a severe INR prolonga-
tion of 14.68, and she was admitted to the intensive care 
unit for worsened general condition. She was transfused with
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Table 1. Basic characteristics of cases and control subjects (n=28)
Characteristic    Cases* Control subjects† p-value
Age (yr) 69.89±9.52  66.37±16.64  0.562
  <60  1 (11.11) 6 (31.58)  0.410
  60-69  4 (44.44) 3 (15.79)
  70-79  2 (22.22) 6 (31.58)
  ≥80  2 (22.22) 4 (21.05)
Sex  1.0
  Male  3 (33.33) 8 (42.11)
  Female  6 (66.67) 11 (57.89)
No. of comorbidities  1.0
  2-3  4 (44.44) 8 (42.11)
  4-5  5 (55.56) 9 (47.37)
  6-7  0 (0) 2 (10.53)
Previous bleeding history  1.0
  No  7 (77.78) 14 (73.68)
  Yes  2 (22.22) 5 (26.32)
Previous admission history‡  1.0
  No  3 (33.33) 7 (36.84)
  Yes  6 (66.67) 12 (63.16)
Activities of daily living§ 18 (6-18) 6 (6-18)    <0.001
  6  1 (11.11) 15 (78.95)  0.001
  9-14  3 (33.33) 3 (15.79)
  18  5 (55.56) 1 (5.26)
Body mass index (kg/m2)  0.771
<19  1 (11.11) 5 (26.32)
19-24  4 (44.44) 8 (42.11)
≥25  4 (44.44) 6 (31.58)
Pressure sore  0.290
  No  6 (66.67) 17 (89.47)
  Yes  3 (33.33) 2 (10.53)
Aspirin use  0.352
  No  6 (66.67) 16 (84.21)
  Yes  3 (33.33) 3 (15.79)
Other antiplatelet agents  1.0
  No  7 (77.78) 13 (68.42)
  Yes  2 (22.22) 6 (31.58)
Ciprofloxacin indication  0.271
  Pneumonia  1 (11.11) 8 (42.11)
 Urinary tract infection  5 (55.56) 6 (31.58)
  Others∥  3 (33.33) 5 (26.32)
Total no. of drug category¶  7.11±2.32 5.47±1.65  0.041
Duration of treatment**  4.67±2.50 7.47±4.15  0.074
Duration of hospitalization 35 (6-375) 21 (3-137)  0.431
Mortality  0.321
  No  8 (88.89) 19 (100)
  Yes  1 (11.11) 0 (0)
Warfarin dosage  2.5 (2-5) 2.5 (1-5)  0.376
Pre‐INR††  2.23 (1.20-4.60) 1.70 (1.19-2.62)  0.052
Maximum INR  6.44 (5.21-14.68) 2.22 (1.21-3.44) <0.001
The values for continuous variables including age, total numbers of drug category, and duration of treatment followed normal distribution. These 
values are expressed as mean±standard deviation, and p‐values were calculated by independent two sample t‐test. ADL, warfarin dosage, pre-INR, 
maximum INR, and duration of hospitalization do not satisfy the normality test and are expressed as median values (minimum value-maximum 
value), and p‐values were obtained by the Mann‐Whitney U test. However, age and ADL can be expressed as categorized variables, shown above as 
total frequency (%). Other categorized variables are shown as total frequency (%), and p-values were calculated by the chi‐square test (Fisher’s exact test).
ADL, activities of daily living; INR, international normalized ratio.
*Cases were chronic anticoagulated patients whose INR increased to >5.0 at any point during the treatment with concurrent use of warfarin and 
ciprofloxacin without increase in the warfarin dose. †Control subjects were enrolled patients whose INR did not increase beyond 3.5 with concurrent 
use of ciprofloxacin and warfarin. ‡History of gastrointestinal bleeding which included cerebral hemorrhage. §Activities of daily living represents 
patients’ performance status. Higher scores reflect greater dependent trends in daily life. ∥Any inflam- matory disease excluding pneumonia and UTI.
¶No. of classes of medications taken by patients. **Length of concurrent use of ciprofloxacin and warfarin.††INR measured 3 days before concurrent use
of ciprofloxacin and warfarin.
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Table 2. Baseline medical history of case group before initiation of ciprofloxacin (n=9)
Case Sex Age (yr) Indications Cormobidities Bleeding* ADL
1 F 68 UTI HTN, DM, VHD, A-fib No 12
2 F 70 Pneumonia CVA, CHF, VHD, A‐fib, Asthma Yes 18
3 F 89 UTI DM, HTN, CVA No 18
4 F 69 FUO (empirical use), Fibrous dysplasia HTN, DM, VHD, A-fib, Hyperthyroidism No  6
5 F 86 UTI DVT, CVA, Osteoporosis, HTN No 18
6 M 58 Cellulitis DM, ESRD, Osteomyelitis No  9
7 M 72 AGE AGC, Meningioma, A‐fib No 13
8 F 63 UTI DM, CAOD, VHD, Colon cancer Yes 18
9 M 72 UTI CKD, CVA, C‐cord injury No 18
ADL, activities of daily living; UTI, urinary tract infection; HTN, hypertension; DM, diabetes mellitus; A‐fib, atrial fibrillation; CVA, 
cerebrovascular disease; CHF, congestive heart failure; VHD, valvular heart disease; FUO, fever unknown origin; DVT, deep vein throm-
bosis; ESRD, end stage renal disease; AGC, advanced gastric cancer; CAOD, coronary artery occlusive disease; CKD, chronic kidney 
disease; C‐cord injury, cervical cord injury.
*Previous history of bleeding‐associated complications due to warfarin use.
Fig. 2. International normalized ratio (INR) distributions to show
drug interaction between ciprofloxacin and warfarin for the case
group (nine subjects). Pre-INRs were measured at admission or 3 
days before initiation of ciprofloxacin and post-INRs were checked
3 days after stopping ciprofloxacin. Max‐INR was the highest INR
measured during treatment. 
fresh frozen plasma and received vitamin K injections to nor-
malize the INR. Five patients (55%) had ADL scores of 18, 
suggesting a poor general condition compared with control 
subjects. No patients died due to INR prolongation; however, 
a patient died because of progression of stomach cancer com-
bined with sepsis (Table 3).
DISCUSSION
There have been many reports of patients on warfarin expe- 
riencing INR prolongation due to enhanced anticoagulation 
effect induced by the concurrent use of antibiotics and other 
drugs. However, most reports were case reports, retrospective 
observations, or studies performed in healthy volunteers; and 
they failed to show statistically significant evidence between drug 
interaction and INR prolongation in acutely ill patients8,21). 
These results support other factors may be at play in the INR 
prolongation. 
We analyzed several factors that were suspected and found 
that patients who had experienced high INR levels had high 
ADL scores and took multiple medications compared to pa-
tients who had not. We could assume that patient condition 
induces coagulopathy because patients who had poor general 
condition tended to have high ADL scores and were generally 
taking many drugs.
Ahmed et al.17) reported that an average of 16% dose reduc-
tion of warfarin before starting trimethoprim-sulfamethox-
azole was helpful in maintaining INR values <4.0 and prevent-
ing development of coagulopathy. However, it was also repor- 
ted that dose reduction of warfarin was not helpful for levo-
floxacin users to maintain target INRs. There is little evidence 
of coagulopathy related to warfarin and levofloxacin inter-
action, and research data has not been able to show guidelines 
for dose reduction before use of antibiotics. Because that report 
was not a randomized study, selection bias and other factors 
may have contributed to the findings. 
Schelleman et al.20) reported that cotrimoxazole and flucona-
zole induced INR prolongation and demonstrated this statis- 
tically. However, they reported that infection and its sequale 
also induced INR prolongation. This result implied that drug 
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Table 3. Progress of case group after treatment with ciprofloxacin (n=9)
Case Hospitalization (day) Pre‐INR* Max‐INR† Post‐INR‡ Cx Time§ (day) Outcome∥ 
1  11  2.38  6.44 1.62 None 3 Healed
2  35  1.92  6.44 1.55 None 3 Healed
3  36  2.44  5.38 2.16 None 2 Healed
4  81  2.11  5.84 1.66 None 2 Healed
 5¶  13  1.20  6.80 3.18 None 2 Expired
6  55 4.6  6.55 3.20 None 2 Healed
7   6  1.63  5.21 1.25 None 2 Healed
8  27  1.45 14.68 1.80 None 1 Healed
9 375  2.37  6.66 2.12 None 2 Healed
Cx, complications; INR, international normalized ratio.
*Patient’s INR 3 days before concurrent use of ciprofloxacin and warfarin. †Patient’s maximum INR during use of ciprofloxacin and war- 
farin concurrently. ‡Patient’s INR 3 days after stopping ciprofloxacin. §Duration of decrease of INR to controlled value. ∥Patient’s status 
after treatment. ¶Case 5: death due to progression of stomach cancer combined with sepsis.
interactions between antibiotics and warfarin were not the 
only factors affecting INR measures.
Although several reports have been published to show drug- 
drug interactions between warfarin and ciprofloxacin, this 
relationship has not yet been proved. What research has demon-
strated is a trend of INR prolongation with concurrent warfarin 
and ciprofloxacin use. Therefore, it is recommended that INR 
should be carefully monitored during therapy with ciproflo- 
xacin4,6-13,17-20). 
We compared patients who had and who did not have INR 
prolongation during concurrent use of warfarin and ciproflo- 
xacin to evaluate additional factors triggering INR prolonga- 
tion. We showed that there was a statistical difference between 
the groups for ADL and the total number of classes of medica- 
tions taken. We adjusted ADL for the items on the Katz ADL 
index, including bathing, dressing, going to toilet, feeding, 
continence, and transferring22,23). Patient performance on each 
item was evaluated. Although each item was classified by 
Katz et al.23) into two categories, dependent and independent, 
we classified them into three categories, independent, partially 
dependent, and fully dependent. For each category, we assigned 
1, 2, and 3 points, respectively. The total score for ADL 
ranged from six to 18. We observed that patients with high 
scores tended to suffer INR prolongation and that total classes 
of pills taken by patients had a positive correlation with coa- 
gulopathy. 
Although previous studies reported that poor general condi- 
tion induced INR prolongation, most results were not quanti- 
fied. In our study, we quantified the general condition through 
the ADL score and presented the correlation between ADL 
score and INR prolongation. We also showed that the total 
classes of drugs taken correlated positively with INR prolon- 
gation. Because patients who had poor conditioning tended 
to be taking more drugs than others, we assumed the total 
classes of drugs could represent a poor general condition. 
Therefore, we are able to use the number of classes of drugs 
as a variable to reflect a patient’s general condition. We expe- 
cted to be reducing the warfarin dose quantitatively according 
to the ADL score as an objective indicator of general condi- 
tioning.
On the other hand, previous reports suggested that INR 
prolongation might develop due only to fever and infection. 
However, both our cases and controls were admitted because 
of infection and fever. Furthermore, we showed that length 
of hospitalization was not statistically related between the 
two groups. Therefore, we thought that INR prolongation 
developed due to acute illness was controlled between the 
groups.
In addition, the samples of previous studies were mostly 
young healthy volunteers. However, we identified cases and 
controls of elderly hospitalized patients who took multiple 
drugs to control variable diseases. Consequently, we expect 
that our results will be clinically valuable for hospitalized 
patients taking several medications with several underlying 
medical problems. No severe complications occurred through-
out this study, and we thought the study progressed safely. 
There were some limitations in this study. Our study was 
neither a multicenter study nor a randomized study. Therefore, 
selection bias was possible. Second, our study is too small to 
be generalized, with a sample size of nine cases and 19 control 
subjects. Although this sample size could possibly show a 
one to one relationship between variables, we could not statisti-
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cally prove one to multiple relationships. Therefore, large 
population studies should be done. Third, our hospitalized 
study sample consumed general diets with the foods being 
different for each individual. Thus, we did not know the 
amount of vitamin K intake by each person nor did we have 
a system to control or quantify it. Generally, patients who 
were in a poor general condition tended to have decreased 
appetite, which might have compromised their nutritional 
status. We cannot ensure that the uncontrolled intake of vita-
min K and poor nutritional status are independent of our 
results. Finally, we identified cases whose INRs were elevated 
>5.0 and control subjects whose INRs were <3.5. As there 
were no objective guidelines to define INR prolongation, we 
used INR range of 2.5-3.5 for postoperative patients with 
mechanical valves and 2.0-3.0 for others. Thus, we attempted 
to achieve an INR value of 2.5 to avoid unexpected hemorrhage 
and to maintain efficacy. An INR >5.0 is not an ordinary 
course of fluctuation and can cause GI bleeding or intracranial 
hemorrhage. We also identified two other groups based on 
the INR value, the <4.0 group and the <5.0 group (data not 
shown). Comparing these two groups with the control group, 
we got the same results as the group with INRs >5.0 (data not 
shown). However, we were uncertain as to whether an INR 
increase to 4.0-5.0 represented INR prolongation or individual 
fluctuation. Therefore, we limited and identified the control 
group as INR <3.5. 
Despite these study limitations, we set an objective index 
for the general conditioning of patients as a triggering factor 
of INR prolongation, with demonstrated statistical signifi- 
cance. If we can overcome the above limitations, we expect 
to be able to present objective guidelines for warfarin dose 
reduction in chronically anticoagulated patients prior to start-
ing antibiotics.
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